Related Experiment Videos
[Geriatric urology -- tumour diseases].
S Krege1, C Friedrich, L Pientka
1Urologische Universitätsklinik Essen. susanne.krege@uni-essen.de
Aktuelle Urologie
|January 28, 2006
Summary
As cancer patients age, urologic malignancies increase, requiring optimized peri-interventional management and tailored treatments. Advances include taxane-based chemotherapy for prostate cancer and gemcitabine for bladder cancer, improving outcomes.
Area of Science:
- Urology
- Oncology
- Geriatrics
Context:
- Increasing prevalence of urogenital malignancies due to demographic shifts and aging populations.
- Growing number of cancer patients presenting with co-morbidities and functional disabilities.
- The rising importance of multidisciplinary care in managing complex urologic cancers.
Purpose:
- To review current advancements in the management of urogenital malignancies.
- To highlight the impact of novel therapeutic strategies on patient survival and toxicity.
- To emphasize the need for individualized treatment approaches in an aging patient cohort.
Summary:
- Optimized peri-interventional management strategies are crucial for reducing surgical risks in urologic oncology.
- Taxane-based chemotherapy regimens have demonstrated survival benefits in hormone-refractory metastatic prostate cancer.
- Gemcitabine shows promise in bladder cancer treatment with reduced toxicity compared to MVAC, while the role of hematopoietic growth factors requires further definition.
Impact:
- Improved patient outcomes through optimized surgical care and effective chemotherapeutic agents.
- Potential for enhanced quality of life and prolonged survival in patients with advanced urogenital cancers.
- The necessity of early collaboration between urologists, oncologists, and geriatricians for personalized cancer care.